dc.contributor.author | Cevik, Mehtap | |
dc.contributor.author | Namal, Esat | |
dc.contributor.author | Sener, Nur Dinc | |
dc.contributor.author | Koksal, Ulkuhan Iner | |
dc.contributor.author | Cagatay, Penbe | |
dc.contributor.author | Deliorman, Gokce | |
dc.contributor.author | Susleyici, Belgin | |
dc.date.accessioned | 2022-11-04T19:55:35Z | |
dc.date.available | 2022-11-04T19:55:35Z | |
dc.date.issued | 2022 | |
dc.identifier.issn | 1741-0541 | |
dc.identifier.issn | 1744-828X | |
dc.identifier.uri | https://doi.org/10.2217/pme-2021-0047 | |
dc.identifier.uri | http://hdl.handle.net/11446/4570 | |
dc.description.abstract | Aim: To investigate the association of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil (5-FU) related toxicities and patient survival. Materials & methods: A total of 103 colorectal cancer patients prescribed 5-FU were included in the study. Genotyping was conducted for several DPYD, MTHFR and TYMS polymorphisms using a microarray analyzer. Results: DPYD 496A>G polymorphism was found to be significantly associated with 5-FU related grade 0-2, but not severe toxicities (p = 0.02). Furthermore, patients with DPYD 85TC and CC genotypes had longer progression and overall survival times compared to TT genotypes in our study group (log rank = 6.60, p = 0.01 and log rank = 4.40, p = 0.04, respectively). Conclusion: According to our results, DPYD 496AG and GG genotypes might be protective against severe adverse events compared to the AA genotype. Another DPYD polymorphism, 85T>C, may be useful in colorectal cancer prognosis. Further studies for both polymorphisms should be conducted in larger populations to achieve accurate results. Plain language summary 5-fluorouracil (5-FU) is a widely used drug for chemotherapy in colorectal cancer. In this study, we investigated the relationship between the severity of 5-FU induced adverse events and several variations in DPYD, MTHFR and TYMS genes, which encode the enzymes involved in 5-FU metabolism in a total of 103 colorectal patients. We also examined the relationship between the polymorphisms and progression-free and overall survival times of the patients in our study group. Among the variations, DPDY 496A>G polymorphism was found to be associated with 5-FU induced adverse events. Also, the DPYD 85T>C polymorphism was detected to be associated with longer progression-free and overall survival times. | en_US |
dc.description.sponsorship | Marmara University Scientific Research Projects Coordination Unit [FEN-C-DRP-1107180407] | en_US |
dc.description.sponsorship | This study was supported by Marmara University Scientific Research Projects Coordination Unit. Project no: FEN-C-DRP-1107180407. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Future Medicine Ltd | en_US |
dc.relation.ispartof | Personalized Medicine | en_US |
dc.identifier.doi | 10.2217/pme-2021-0047 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | en_US |
dc.subject | adverse effects | en_US |
dc.subject | colorectal cancer | en_US |
dc.subject | DPYD | en_US |
dc.subject | fluoropyrimidines | en_US |
dc.subject | MTHFR | en_US |
dc.subject | pharmacogenetics | en_US |
dc.subject | polymorphisms | en_US |
dc.subject | TYMS | en_US |
dc.subject | Dihydropyrimidine Dehydrogenase Gene | en_US |
dc.subject | Methylenetetrahydrofolate Reductase | en_US |
dc.subject | Thymidylate-Synthase | en_US |
dc.subject | Capecitabine | en_US |
dc.subject | Variants | en_US |
dc.subject | Metabolism | en_US |
dc.subject | Efficacy | en_US |
dc.subject | Predict | en_US |
dc.subject | Pharmacokinetics | en_US |
dc.subject | Dpyd-Asterisk-2a | en_US |
dc.title | Investigation of DPYD, MTHFR and TYMS polymorphisms on 5-fluorouracil related toxicities in colorectal cancer | en_US |
dc.type | article | en_US |
dc.identifier.issue | 5 | en_US |
dc.identifier.volume | 19 | en_US |
dc.identifier.startpage | 435 | en_US |
dc.identifier.endpage | 444 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.department-temp | [Cevik, Mehtap; Susleyici, Belgin] Marmara Univ, Dept Mol Biol, Fac Arts & Sci, TR-34722 Istanbul, Turkey; [Namal, Esat; Sener, Nur Dinc] Demiroglu Bilim Univ, Dept Med Oncol, Fac Med, TR-34394 Istanbul, Turkey; [Koksal, Ulkuhan Iner] Istanbul Bagcilar Training & Res Hosp, TR-34200 Istanbul, Turkey; [Cagatay, Penbe] Istanbul Univ Cerrahpasa, Vocat Sch Hlth Serv, Dept Med Serv & Tech, TR-34320 Istanbul, Turkey; [Deliorman, Gokce] Beykoz Univ, Dept Software Engn, Fac Engn & Architecture, TR-34810 Istanbul, Turkey; [Ciftci, Cavlan] Demiroglu Bilim Univ, Dept Cardiol, Fac Med, TR-34394 Istanbul, Turkey; [Karaalp, Atila] Marmara Univ, Dept Med Pharmacol, Fac Med, TR-34854 Istanbul, Turkey | en_US |
dc.authorid | Karaalp, Atila/0000-0003-3382-9483 | |
dc.identifier.pmid | 35880438 | en_US |
dc.identifier.scopus | 2-s2.0-85138447228 | en_US |
dc.identifier.wos | WOS:000829836200001 | en_US |
dc.authorscopusid | 57216620714 | |
dc.authorscopusid | 36667213900 | |
dc.authorscopusid | 55555100000 | |
dc.authorscopusid | 56123720900 | |
dc.authorscopusid | 6507755715 | |
dc.authorscopusid | 57216614327 | |
dc.authorscopusid | 15821728300 | |